Alumis Inc. (ALMS)
| Market Cap | 2.90B +465.8% |
| Revenue (ttm) | 7.40M -63.1% |
| Net Income | -438.96M |
| EPS | -3.80 |
| Shares Out | 129.44M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 655,332 |
| Open | 22.83 |
| Previous Close | 23.21 |
| Day's Range | 22.35 - 23.28 |
| 52-Week Range | 3.76 - 31.35 |
| Beta | -0.67 |
| Analysts | Strong Buy |
| Price Target | 40.33 (+80.21%) |
| Earnings Date | Aug 13, 2026 |
About ALMS
Alumis Inc., a clinical stage biopharmaceutical company, focuses on the development and commercialization of medicines for autoimmune disorders. The company offers envudeucitinib, a tyrosine kinase 2 (TYK2) inhibitor for the treatment of plaque psoriasis and systemic lupus erythematosus; and A-005, a central nervous system-penetrant allosteric TYK2 inhibitor that is in Phase 1 for the treatment of neuroinflammatory and neurodegenerative diseases. It also develops lonigutamab, a monoclonal antibody targeting IGF-1R for the treatment of thyroid e... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 10 analysts, the average rating for ALMS stock is "Strong Buy." The 12-month stock price target is $40.33, which is an increase of 80.21% from the latest price.
News
Alumis reports Q2 revenue $1.66M, consensus $3.47M
“Envudeucitinib’s Phase 3 clinical validation in PsO, reinforced by our ONWARD3 long-term data, demonstrates the power of maximal TYK2 inhibition in IL-23/IL-17-driven diseases, and our anticipated Ph...
Alumis Reports Second Quarter 2026 Financial Results and Highlights Recent Achievements
– ONWARD3: 54% of patients reached complete skin clearance (PASI 100) at 48 weeks, positioning envudeucitinib to set a new standard in PsO –
Alumis Earnings release: Q2 2026
Alumis released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Alumis Quarterly report: Q2 2026
Alumis has published its Q2 2026 quarterly earnings report on August 13, 2026.
Alumis announces topline results from ONWARD3 long-term extension study
Alumis (ALMS) announced topline results from the ongoing ONWARD3 long-term extension study. Data confirm envudeucitinib delivered leading skin clearance and the highest reported Psoriasis Area and Sev...
Alumis Slides: Corporate presentation
Alumis has posted slides in relation to its latest quarterly earnings report, which was published on August 1, 2026.
Alumis management to meet with Cantor
Meeting to be held in London on June 30 and in Zurich on July 1 hosted by Cantor.
Alumis price target raised to $40 from $38 at Chardan
Chardan raised the firm’s price target on Alumis (ALMS) to $40 from $38 and keeps a Buy rating on the shares, reflecting updated pricing assumptions for envudeucitinib, modest changes in…
Alumis Proxy statement: Proxy filing
Alumis filed a proxy statement on May 18, 2026, providing details for shareholder voting and corporate governance matters.
Alumis Proxy statement: Proxy filing
Alumis filed a proxy statement on May 18, 2026, providing details for shareholder voting and corporate governance matters.
Alumis price target raised to $39 from $38 at Morgan Stanley
Morgan Stanley analyst Terence Flynn raised the firm’s price target on Alumis (ALMS) to $39 from $38 and keeps an Overweight rating on the shares.
Alumis price target raised to $51 from $49 at Wells Fargo
Wells Fargo raised the firm’s price target on Alumis (ALMS) to $51 from $49 and keeps an Overweight rating on the shares. The firm believes the Street-implied probability of success…
Alumis Slides: Corporate presentation
Alumis has posted slides in relation to its latest quarterly earnings report, which was published on May 15, 2026.
Alumis price target raised to $34 from $32 at Guggenheim
Guggenheim analyst Yatin Suneja raised the firm’s price target on Alumis (ALMS) to $34 from $32 and keeps a Buy rating on the shares. The firm’s raised target reflects the…
Alumis downgraded to Neutral from Buy at H.C. Wainwright
H.C. Wainwright analyst Mitchell Kapoor downgraded Alumis (ALMS) to Neutral from Buy with an unchanged price target of $25. The firm cites valuation for the downgrade. The current share price…
Alumis reports Q1 net loss of $93.1M vs. net loss of $99.0M last year
Reports Q1 revenue $1.74M, consensus $2.49M. As of March 31, Alumis (ALMS) had cash, cash equivalents and marketable securities of $569.5M. “Alumis delivered a focused and productive first quarter, bu...
Alumis Reports First Quarter 2026 Financial Results and Highlights Recent Achievements
– Late-breaking oral presentation of Phase 3 envudeucitinib data in moderate-to-severe plaque psoriasis (PsO) at the 2026 American Academy of Dermatology (AAD) Annual Meeting demonstrating early and r...
Alumis Earnings release: Q1 2026
Alumis released its Q1 2026 earnings on May 14, 2026, summarizing the period's financial results.
Alumis Quarterly report: Q1 2026
Alumis has published its Q1 2026 quarterly earnings report on May 14, 2026.
Alumis shares should trade higher on ‘major success’ at AAD, says Ramond James
Raymond James keeps a Strong Buy rating on Alumis (ALMS) following what appears to be a major success at AAD, where Phase 3 data showed envudeucitinib delivering efficacy broadly comparable…
Alumis price target raised to $55 from $50 at Oppenheimer
Oppenheimer raised the firm’s price target on Alumis to $55 from $50 and keeps an Outperform rating on the shares. The firm sees the three new orals for psoriasis –…
Alumis price target lowered to $25 from $40 at H.C. Wainwright
H.C. Wainwright analyst Mitchell Kapoor lowered the firm’s price target on Alumis (ALMS) to $25 from $40 and keeps a Buy rating on the shares. The firm says the oral…
Alumis Transcript: Study update
Envudeucitinib’s phase III ONWARD trials showed robust skin clearance, rapid itch reduction, and strong quality-of-life improvements in moderate to severe plaque psoriasis, with a favorable safety profile through 24 weeks. Its efficacy, especially in itch relief, positions it as a leading oral option, with further studies planned.